Lead Investigator: Robert Hamilton, University of Toronto
Title of Proposal Research: Statin use and prostate cancer outcomes in patients treated in the ARAMIS trial
Vivli Data Request: 8602
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Prostate cancer (PCa) remains the most commonly diagnosed disease in Canadian men and is the third leading cause of cancer-related death. In 2016, an estimated 21,600 men were diagnosed with prostate cancer and 4000 men died from the disease.
Men with PCa are usually elderly and tend to have other concomitant diseases like high blood pressure, high cholesterol, prior stroke etc. Hence, in addition to their medications to manage PCa, a vast majority require additional medicines like statins. Statins are a group of drugs that act to reduce levels of fats, including triglycerides and cholesterol, in the blood. Statins may also reduce inflammation in the artery walls, which could prevent blockages that damage organs such as the heart and brain. There is increasing interest in statin medications as inhibitors of PCa development and growth. Studies have shown positive associations between statin use and PCa outcomes, though nearly all the studies have been “retrospective” meaning the data had already been collected (perhaps for another reason) and researchers went back to look at the statin-cancer associations.
Metastatic castrate resistant prostate cancer (mCRPC) is a prostate cancer that has spread to other parts of the body, and which keeps growing even when the amount of male hormones in the body are reduced to very low levels. Reducing the male hormones, called androgens, in the body is essential to stop them from fueling prostate cancer cell growth. This can be achieved by either by surgically removing the testes and/or by using newer medicines called Androgen receptor-axis-targeted therapies (ARATs). Our proposal specifically looks at Darolutamide, an ARAT, and statin use because Darolutamide is a newer medicine offering efficacy in controlling PCa and least toxic compared to other ARATs.
In mCRPC disease, the data regarding statins and outcomes are conflicting. It may be that in earlier disease settings, where survival times are longer, more of a benefit attributable to statin use would be observed. A few mechanisms have been suggested that statins may heighten novel androgen receptor inhibitors like darolutamide, including: hampering of steroid hormone production by the tumor itself, inhibition of production of other elements of the cholesterol pathway, as well as inhibition of androgens (male hormone) being brought into the cancer cells. Androgens serve as food for the prostate cancer cells to grow. Recently our group showed giving men with statins prior to surgical removal of prostate lead to signs that the cancer cells were dying and this was more pronounced in men on statins for longer periods.
Darolutamide is the newest and least toxic ARAT approved for delaying metastasis and overall survival in non-metastatic castration sensitive prostate cancer (nmCRPC). nmCRPC is a diverse disease state where the cancer hasn’t spread, male hormone testosterone is not detected in blood with a confirmed rising prostate-specific androgen (PSA) level. PSA test is used to monitor men after surgery or radiation therapy for prostate cancer to see if their cancer has come back.
To date, no prospective clinical trials in PCa have evaluated statin use in combination with other anti-cancer treatments, although our lab remains very interested in the hypothesis of synergy between statins and other drugs that may influence the cholesterol metabolism pathway and other prostate cancer therapies (including androgen axis inhibitors like darolutamide, the subject of the proposed study).
Requested Studies:
A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
Data Contributor: Bayer
Study ID: NCT02200614
Sponsor ID: 17712